Shots:
- The global diagnostics market is rapidly evolving through AI-powered imaging, molecular testing, precision medicine, and digital pathology solutions. In 2025, Siemens Healthineers led the industry with $20.54B in diagnostics revenue, followed by Roche at $17.52B and GE HealthCare at $17.49B, reflecting the growing adoption of advanced imaging, lab automation, and AI-driven diagnostics across global healthcare systems
- Valued at $209.48B in 2025, the diagnostics market is projected to reach $274.53B by 2034. The ranking of leading diagnostics companies is based on diagnostics segment revenue generated between January and December 2025, with revenues standardized into US dollars using year-end exchange rates
- The “Top 20 Diagnostics Companies of 2026” report highlights industry leaders advancing innovation in diagnostic imaging, molecular testing, pathology, genomics, and laboratory solutions. Key market trends include strong growth in molecular diagnostics, companion diagnostics, laboratory automation, AI-enabled imaging, precision oncology testing, and strategic acquisitions that continue to reshape the competitive diagnostics landscape
20. Revvity
Diagnostic Segment Revenue: $1.42B
Founded Year: 1947
Total Employees: 11,000
Headquarters: Massachusetts, United States
Market Cap: $10.42B
Stock Exchange: NYSE
- Revvity is a global health science and diagnostics company that provides solutions across life sciences and diagnostics markets. The company operates through segments including Diagnostics and Life Sciences, offering technologies in immunodiagnostics, reproductive health, infectious disease testing, genomics, imaging, and laboratory automation
- Revvity reported diagnostics revenue of $1.42B in 2025 compared to $1.35B in 2024, reflecting ~5.2% growth YoY, primarily driven by increased global sales and strong demand across its diagnostics portfolio. Key diagnostic products and services include EUROIMMUN immunodiagnostic assays, IDS automated chemiluminescence immunoassays (ChLIA), newborn screening solutions, reproductive health diagnostics, and molecular testing platforms
- In May 2026, Revvity announced that the US FDA cleared its Total Testosterone automated ChLIA assay through its subsidiary Immunodiagnostic Systems (IDS), enabling a comprehensive automated testosterone testing solution on a single platform for endocrine disorder diagnostics
19. Lantheus Holdings
Diagnostic Segment Revenue: $1.48B
Founded Year: 1956
Total Employees: 1,200
Headquarters: Massachusetts, United States
Market Cap: $10.42B
Stock Exchange: NASDAQ
- Lantheus Holdings is a radiopharmaceutical-focused company specializing in diagnostic imaging and therapeutic solutions. The company operates across segments including Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships, with products supporting oncology, cardiology, and neurology imaging applications
- Lantheus reported revenue of $1.48B in 2025 compared to $1.49B in 2024, reflecting a slight decline of ~0.7% YoY, primarily driven by lower sales of PYLARIFY amid competitive pricing pressure in the PSMA PET imaging market. Key diagnostic products and services include PYLARIFY, DEFINITY, Neuraceq, and TechneLite imaging agents
- In March 2026, Lantheus announced US FDA approval of PYLARIFY TruVu (piflufolastat F18), a new formulation of its prostate cancer imaging agent designed to improve manufacturing efficiency, increase production capacity, and expand access to PSMA PET imaging
18. Bio-Rad Laboratories
Diagnostic Segment Revenue: $1.56B
Founded Year: 1952
Total Employees: 7,400
Headquarters: California, United States
Market Cap: $10.42B
Stock Exchange: NYSE
- Bio-Rad Laboratories is a global provider of life science research and clinical diagnostics products. The company operates through two major segments: Life Science, which includes genomics, proteomics, cell biology, and droplet digital PCR technologies, and Clinical Diagnostics, which focuses on quality controls, immunohematology, diabetes monitoring, and infectious disease testing solutions
- Bio-Rad reported revenue of $1.56B in 2025 compared to $1.53B in 2024, reflecting ~2.0% YoY growth, primarily supported by strength in its quality control portfolio within the Clinical Diagnostics segment. Key diagnostic products and services include BioPlex systems, IH-500 immunohematology analyzers, Unity quality control solutions, diabetes testing products, and Droplet Digital PCR (ddPCR) platforms
- In September 2025, Bio-Rad announced the expansion of its Droplet Digital PCR portfolio through a strategic acquisition and rollout of new ddPCR platforms aimed at enhancing precision molecular diagnostics and research applications
17. Eurofins Scientific
Diagnostic Segment Revenue: $1.75B
Founded Year: 1987
Total Employees: 65,700
Headquarters: Luxembourg
Market Cap: $10.42B
Stock Exchange: EPA
- Eurofins Scientific is a global laboratory testing and diagnostics company providing services across pharmaceuticals, food, environmental, clinical diagnostics, and life sciences markets. The company operates through segments including Clinical Diagnostics, Food & Feed Testing, BioPharma Services, Environment Testing, and Consumer Product Testing
- Eurofins Scientific reported revenue of $1.75B in 2025 compared to $1.42B in 2024, reflecting ~23.2% YoY growth, primarily driven by expansion in its Clinical Diagnostics business in Europe following the acquisition of SYNLAB’s clinical diagnostics operations in Spain in March 2025. Key diagnostic products and services include clinical laboratory testing, genetic testing, esoteric diagnostics, pathology services, infectious disease testing, and biomarker analysis solutions
- In March 2025, Eurofins announced the successful closing of its acquisition of SYNLAB’s clinical diagnostics operations in Spain, significantly strengthening its clinical diagnostics footprint and laboratory network across Europe
16. Hologic
Diagnostic Segment Revenue: $1.82B
Founded Year: 1985
Total Employees: 7,100
Headquarters: Massachusetts, United States
Market Cap: $10.42B
Stock Exchange: N/A
- Hologic is a global medical technology company focused on women’s health and diagnostic solutions. The company operates through segments including Diagnostics, Breast Health, GYN Surgical, and Skeletal Health, providing molecular diagnostics, cytology, imaging systems, and surgical products worldwide
- Hologic reported revenue of $1.82B in 2025 compared to $1.68B in 2024, reflecting ~8.3% YoY growth, primarily due to increased overall sales across its diagnostics and women’s health portfolio. Key diagnostic products and services include the Panther molecular diagnostics platform, Aptima assays, ThinPrep cytology systems, BV/CV/TV women’s health assays, and respiratory testing solutions
- In April 2026, Hologic announced the completion of its acquisition by Blackstone and TPG, a transaction expected to support continued expansion and innovation across its diagnostics and women’s health businesses
15. Natera
Diagnostic Segment Revenue: $2.3B
Founded Year: 2004
Total Employees: 6,100
Headquarters: Texas, United States
Market Cap: $10.42B
Stock Exchange: NASDAQ
- Natera is a global diagnostics company focused on cell-free DNA and genetic testing technologies. The company operates across segments including Oncology, Women’s Health, and Organ Health, providing molecular diagnostics solutions for cancer detection, prenatal screening, and transplant monitoring
- Natera reported revenue of $2.3B in 2025 compared to $1.69B in 2024, reflecting ~36.1% YoY growth, primarily driven by strong sales growth in the United States across its oncology and genetic testing portfolio. Key diagnostic products and services include Signatera MRD testing, Panorama NIPT, Horizon carrier screening, Prospera transplant assessment, and Altera genomic profiling solutions
- In April 2025, Natera announced that the US FDA approved Signatera CDx as a companion diagnostic for muscle-invasive bladder cancer (MIBC), expanding the clinical utility of its personalized molecular residual disease (MRD) testing platform in oncology diagnostics
14. QuidelOrtho
Diagnostic Segment Revenue: $2.73B
Founded Year: 1979
Total Employees: 6,500
Headquarters: California, United States
Market Cap: $10.42B
Stock Exchange: NASDAQ
- QuidelOrtho is a global diagnostics company specializing in in-vitro diagnostic technologies and laboratory solutions. The company operates through segments including Labs, Transfusion Medicine, Molecular Diagnostics, Immunohematology, and Point of Care, serving hospitals, laboratories, blood banks, and healthcare providers worldwide
- QuidelOrtho reported revenue of $2.73B in 2025 compared to $2.78B in 2024, reflecting a decline of ~1.8% YoY, primarily driven by lower sales in its Donor Screening and Point of Care businesses. Key diagnostic products and services include Sofia rapid diagnostic systems, Savanna molecular testing platform, VITROS laboratory analyzers, Ortho Vision blood typing systems, and donor screening assays
- In April 2025, QuidelOrtho announced the completion of its acquisition of LEX Diagnostics, strengthening its rapid molecular diagnostics portfolio and expanding capabilities in ultra-fast point-of-care PCR testing
13. Bruker
Diagnostic Segment Revenue: $3.17B
Founded Year: 1960
Total Employees: 12,000
Headquarters: Massachusetts, United States
Market Cap: $10.42B
Stock Exchange: NASDAQ
- Bruker is a global provider of scientific instruments, analytical technologies, and diagnostics solutions serving life sciences, pharma, microbiology, and applied markets. The company operates through segments including Bruker Scientific Instruments (BSI) and Bruker Energy & Supercon Technologies (BEST), with the BSI CALID segment focused on cellular analysis, life science mass spectrometry, microbiology, and diagnostics
- Bruker reported revenue of $3.17B in 2025 compared to $3.09B in 2024, reflecting ~2.6% YoY growth, primarily driven by higher sales in the BSI CALID segment. Key diagnostic products and services include the MALDI Biotyper microbial identification platform, IR Biotyper strain typing solution, timsTOF mass spectrometry systems, and molecular diagnostics technologies for clinical microbiology and infectious disease testing
- In February 2026, Bruker announced expanded workflows for its MALDI Biotyper and IR Biotyper platforms to enhance microbial identification and outbreak management capabilities in clinical microbiology diagnostics laboratories
12. Sysmex
Diagnostic Segment Revenue: $3.21B
Founded Year: 1968
Total Employees: 10,500
Headquarters: Kobe, Japan
Market Cap: $10.42B
Stock Exchange: TYO
- Sysmex is a global diagnostics company specializing in clinical laboratory testing and healthcare solutions. The company operates through segments including Hematology, Hemostasis, Urinalysis, Immunochemistry, and Life Science, providing instruments, reagents, and software solutions for hospitals and clinical laboratories worldwide
- Sysmex reported revenue of $3.21B in 2025 compared to $3.15B in 2024, reflecting ~1.9% YoY growth, primarily driven by an overall increase in sales across its diagnostics portfolio. Key diagnostic products and services include XN-Series hematology analyzers, CN-Series hemostasis systems, UF-Series urinalysis platforms, HISCL immunoassay systems, and clinical laboratory automation solutions
- On April 13, 2026, Sysmex announced the launch of a new testing solution aimed at improving diagnostic efficiency and expanding its clinical laboratory capabilities, further strengthening its diagnostics portfolio
11. Canon
Diagnostic Segment Revenue: $3.71B
Founded Year: 1937
Total Employees: 1,65,500
Headquarters: Tokyo, Japan
Market Cap: $10.42B
Stock Exchange: TYO
- Canon is a global technology company specializing in imaging, healthcare, and industrial solutions. The company operates through segments including Printing, Medical, Imaging, and Industrial, with its Medical business focused on diagnostic imaging systems, healthcare IT, and ultrasound technologies
- Canon reported revenue of $3.71B in 2025 compared to $3.61B in 2024, reflecting ~2.8% YoY growth, primarily driven by higher sales across its healthcare and imaging portfolio. Key diagnostic products and services include Aplio ultrasound systems, Aquilion CT scanners, Vantage MRI systems, digital radiography solutions, and healthcare imaging IT platforms
- In May 2026, Olympus and Canon Medical introduced the Aplio i800 EUS premium ultrasound system in the United States, expanding advanced endoscopic ultrasound imaging capabilities for gastroenterology and diagnostic procedures
10. IDEXX Laboratories
Diagnostic Segment Revenue: $4.1B
Founded Year: 1983
Total Employees: 11,000
Headquarters: Westbrook, United States
Market Cap: $10.42B
Stock Exchange: NASDAQ
- IDEXX Laboratories is a global leader in veterinary diagnostics and healthcare solutions. The company operates through segments including Companion Animal Group (CAG), Water Quality Products, Livestock, Poultry & Dairy (LPD), and Diagnostics Imaging, providing laboratory testing, software, imaging, and point-of-care diagnostic solutions for veterinary practices worldwide
- IDEXX Laboratories reported revenue of $4.1B in 2025 compared to $3.71B in 2024, reflecting ~10.5% YoY growth, primarily driven by increased sales in both US and international markets. Key diagnostic products and services include Catalyst chemistry analyzers, ProCyte hematology systems, SNAP rapid assays, VetConnect PLUS software, ImageVue imaging systems, and reference laboratory services
- On January 2026, IDEXX announced the launch of the ImageVue DR50 Plus imaging system, introducing advanced low-dose radiography capabilities designed to enhance diagnostic imaging quality and workflow efficiency in veterinary practices
9. Thermo Fisher Scientific
Diagnostic Segment Revenue: $4.67B
Founded Year: 1956
Total Employees: 1,25,000
Headquarters: Massachusetts, United States
Market Cap: $10.42B
Stock Exchange: NYSE
- Thermo Fisher Scientific is a global provider of scientific instruments, diagnostics, laboratory services, and life sciences solutions. The company operates through segments including Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products & Biopharma Services, serving healthcare, pharmaceutical, academic, and industrial markets worldwide
- Thermo Fisher Scientific reported revenue of $4.67B in 2025 compared to $4.51B in 2024, reflecting ~3.5% YoY growth, primarily driven by growth in the healthcare market channel and the transplant diagnostics business. Key diagnostic products and services include transplant diagnostics solutions, ImmunoCAP allergy testing systems, MAS quality controls, molecular diagnostic assays, and clinical laboratory instruments
- In February 2026, Thermo Fisher Scientific announced that its PPD clinical research business expanded bioanalytical capabilities with a new laboratory in Gothenburg, Sweden, strengthening support for clinical diagnostics and biopharmaceutical research services
8. Becton-Dickinson and Company
Diagnostic Segment Revenue: $5.09B
Founded Year: 1897
Total Employees: 72,000
Headquarters: New Jersey, United States
Market Cap: $10.42B
Stock Exchange: NYSE
- Becton, Dickinson and Company is a global medical technology company focused on diagnostics, biosciences, medication delivery, and interventional solutions. The company operates through segments including BD Medical, BD Life Sciences, and BD Interventional, offering products and services for clinical diagnostics, specimen collection, flow cytometry, microbiology, and healthcare safety solutions
- Becton, Dickinson and Company reported revenue of $5.09B in 2025 compared to $5.2B in 2024, reflecting a decline of ~2.1% YoY, primarily due to the separation of the Specimen Management business from the Life Sciences segment. Key diagnostic products and services include BD MAX molecular diagnostic systems, BD Kiestra microbiology automation, flow cytometry platforms, Veritor rapid diagnostic systems, and specimen collection solutions
- In March 2026, BD announced US FDA clearance for Surgiphor 1000mL for wound irrigation, introducing an advanced surgical safety solution designed to support infection prevention and improve procedural outcomes in healthcare settings
7. Abbott Laboratories
Diagnostic Segment Revenue: $8.93B
Founded Year: 1888
Total Employees: 1,15,000
Headquarters: Illinois, United States
Market Cap: $10.42B
Stock Exchange: NYSE
- Abbott Laboratories is a global healthcare company operating across segments including Diagnostics, Medical Devices, Nutrition, and Established Pharmaceuticals. Its diagnostics business provides core laboratory, molecular, point-of-care, and rapid testing solutions for hospitals, laboratories, and healthcare providers worldwide
- Abbott Laboratories reported revenue of approximately $8.93B in 2025 compared to $9.34B in 2024, reflecting a decline of ~4.4% YoY, primarily due to lower sales in both US and international markets. Key diagnostic products and services include the Alinity family of diagnostic systems, ARCHITECT laboratory platforms, ID NOW molecular testing, BinaxNOW rapid diagnostics, and cardiovascular imaging solutions
- In April 2026, Abbott announced that it received US FDA clearance and CE Mark approval for its next-generation Ultreon 3.0 AI-powered coronary imaging platform, designed to enhance intravascular imaging and support precision cardiovascular diagnostics and interventions
6. Danaher
Diagnostic Segment Revenue: $9.94B
Founded Year: 1984
Total Employees: 59,000
Headquarters: Washington, DC, United States
Market Cap: $10.42B
Stock Exchange: NYSE
- Danaher is a global science and technology innovator providing solutions across diagnostics, life sciences, and biotechnology markets. The company operates through segments including Biotechnology, Life Sciences, and Diagnostics, delivering instruments, consumables, software, and laboratory solutions worldwide
- Danaher reported revenue of approximately $9.94B in 2025 compared to $9.78B in 2024, reflecting ~1.6% YoY growth, primarily driven by an increase in overall sales across its diagnostics segment. Key diagnostic products and services include Cepheid molecular diagnostic systems, Beckman Coulter clinical diagnostics platforms, Leica Biosystems pathology solutions, and Radiometer blood gas analyzers
- In February 2026, Danaher announced plans to acquire Masimo Corporation, a move expected to strengthen its diagnostics and patient monitoring portfolio while expanding capabilities in healthcare technology and clinical diagnostics
5. Philips Healthcare
Diagnostic Segment Revenue: $10.03B
Founded Year: 1891
Total Employees: 64,300
Headquarters: Amsterdam, Netherlands
Market Cap: $10.42B
Stock Exchange: AMS
- Philips Healthcare is a global healthcare technology company focused on diagnostic imaging, patient monitoring, image-guided therapy, and healthcare informatics. The company operates through segments including Diagnosis & Treatment, Connected Care, and Personal Health, delivering advanced imaging systems, monitoring solutions, and clinical workflow technologies worldwide
- Philips Healthcare reported revenue of $10.03B in 2025 compared to $9.15B in 2024, reflecting ~9.6% YoY growth in reported currency terms, primarily supported by favorable foreign exchange rates despite a decline in Euro-based sales performance. Key diagnostic products and services include MRI systems, CT scanners, ultrasound platforms, image-guided therapy solutions, patient monitoring systems, and healthcare informatics software
- In April 2026, Philips received US FDA 510(k) clearance for its Smart Fit Torso/Cardiac Coil for 1.5T MR imaging, designed to improve patient comfort and streamline MRI diagnostic workflows
4. Quest Diagnostics
Diagnostic Segment Revenue: $11.03B
Founded Year: 1967
Total Employees: 51,500
Headquarters: New Jersey, United States
Market Cap: $10.42B
Stock Exchange: NYSE
- Quest Diagnostics is a leading provider of diagnostic information services, offering laboratory testing, pathology, genomic testing, and data analytics solutions. The company operates across segments including Diagnostic Information Services (DIS) and Diagnostic Solutions, serving physicians, hospitals, health systems, employers, and patients worldwide
- Quest Diagnostics reported revenue of $11.03B in 2025 compared to $9.87B in 2024, reflecting ~11.8% YoY growth, primarily driven by overall business growth across its diagnostic testing and healthcare services portfolio. Key diagnostic products and services include advanced molecular diagnostics, oncology testing, genetic and hereditary disease testing, pathology services, infectious disease diagnostics, and Quanum healthcare IT solutions
- In February 2026, Quest Diagnostics announced the launch of a novel flow cytometry minimal residual disease (MRD) blood test for myeloma, enabling ultrasensitive detection of residual disease to support improved cancer monitoring and treatment management
3. GE Healthcare
Diagnostic Segment Revenue: $17.49B
Founded Year: 1994
Total Employees: 54,000
Headquarters: Chicago, Illinois
Market Cap: $10.42B
Stock Exchange: NASDAQ
- GE HealthCare is a global healthcare technology company providing diagnostic imaging, pharmaceutical diagnostics, patient monitoring, and digital healthcare solutions. The company operates through segments including Imaging, Advanced Visualization Solutions (AVS), Pharmaceutical Diagnostics (PDx), and Patient Care Solutions, serving hospitals and healthcare providers worldwide
- GE HealthCare reported revenue of $17.49B in 2025 compared to $16.49B in 2024, reflecting ~6.1% YoY growth, primarily driven by increased sales across all major diagnostic segments, including Imaging, AVS, and PDx. Key diagnostic products and services include MRI and CT imaging systems, PET radiopharmaceuticals, ultrasound platforms, molecular imaging agents, and AI-enabled diagnostic workflow solutions
- In February 2026, GE HealthCare introduced MIM ComboTherapy GYN HDR EBRT, an advanced solution designed to improve precision in gynecologic cancer care through enhanced imaging, radiation therapy planning, and treatment workflow integration
2. Roche
Diagnostic Segment Revenue: $17.52B
Founded Year: 1896
Total Employees: 1,13,000
Headquarters: Basel, Switzerland
Market Cap: $10.42B
Stock Exchange: SWX
- Roche is a global healthcare company operating through two primary divisions: Pharmaceuticals and Diagnostics. Its diagnostics division provides solutions across molecular diagnostics, tissue diagnostics, immunodiagnostics, sequencing, diabetes care, and digital pathology for hospitals, laboratories, and research institutions worldwide
- Roche reported revenue of $17.52B in 2025 compared to $15.85B in 2024, reflecting ~10.5% YoY growth in reported currency terms, primarily supported by favorable foreign exchange rates despite weaker Euro-based sales performance. Key diagnostic products and services include the cobas molecular diagnostics platform, Elecsys immunoassays, Ventana tissue diagnostics systems, Navify digital healthcare solutions, and blood glucose monitoring technologies
- In May 2026, Roche announced advancements in its diagnostics portfolio during Roche Diagnostics Day 2026, highlighting digital pathology, AI-enabled companion diagnostics, molecular laboratory innovations, and new diagnostic pipeline developments
1. Siemens Healthineers
Diagnostic Segment Revenue: $20.54B
Founded Year: 1847
Total Employees: 74,000
Headquarters: Forchheim, Germany
Market Cap: $10.42B
Stock Exchange: ETR
- Siemens Healthineers is a global healthcare technology company focused on diagnostic imaging, laboratory diagnostics, advanced therapies, and digital health solutions. The company operates through segments including Imaging, Diagnostics, Varian, and Advanced Therapies, serving hospitals, laboratories, and healthcare providers worldwide
- Siemens Healthineers reported revenue of $20.54B in 2025 compared to $17.37B in 2024, reflecting ~18.2% YoY growth, primarily driven by overall sales increases across its diagnostic and imaging businesses. Key diagnostic products and services include Atellica diagnostic analyzers, MAGNETOM MRI systems, SOMATOM CT scanners, syngo software solutions, and molecular imaging technologies
- In May 2026, Siemens Healthineers announced advancements in CT-guided PCI procedures, highlighting new imaging technologies designed to improve precision in interventional cardiology and support enhanced diagnostic and treatment workflows
Criteria:
- The report is based on companies’ diagnostics segment revenue for the period January to December 2025 only
- For Japanese companies or those with non-December fiscal year endings, revenue has been calculated for the January–December period using their quarterly filings
- Revenues reported in different currencies have been converted into US dollars using exchange rates as of 31 December 2025
Source:
- Company Websites
- Press Releases
- Annual Reports
- Quarterly Reports
- Google Finance
- OANDA
Related Post: Top 20 Diagnostics Companies of 2025
